Positive interim clinical data in allergic children treated with Viaskin Peanut

French allergy specialist DBV Technologies (Euronext: DBV), creator of Viaskin, a new standard in the treatment of allergy, says that AP-HP (Assistance Public – Hopitaux de Paris) sponsor of the ARACHILD study presented positive safety and efficacy data after six months of epicutaneous immunotherapy in peanut allergy using Viaskin Peanut at the European Academy of Allergy and Clinical Immunology (EAACI) Congress.

Peanut allergy is a potential life threatening disease for millions of people without any available effective medical treatments. DBV Technologies is developing Viaskin Peanut for the global market with several ongoing clinical studies in both Europe and in the USA.

The ongoing ARACHILD study which is a multicenter double blind placebo-controlled 18 month clinical trial is designed to assess the efficacy and safety of Viaskin Peanut in 54 randomized children aged five to 17 years with a confirmed peanut allergy. Importantly, the six months interim data show no drop-out of patients from the study due to adverse events or any serious adverse events related to the treatment.